Dr. Philip McMillan, John McMillan
A recent study published in ‘Nature Medicine’ has sparked significant discussion throughout the medical community regarding the longevity of immunity provided by mRNA COVID-19 vaccines. Dr. Philip McMillan, a researcher who has been examining pandemic responses for over four years, shared his insights on this groundbreaking paper titled “SARS-CoV-2-Specific Plasma Cells Are Not Durably Established in the Bone Marrow Long-Lived Compartment After mRNA Vaccination.” in a recent VejonHealth episode.
“This paper is a significant piece of the puzzle,” Dr. McMillan commented. “It helps us understand why antibody levels wane so quickly after each COVID vaccine dose.” The study investigates the mechanism behind the rapid decline of antibodies post-vaccination, a phenomenon that has led to the administration of multiple booster doses.
Understanding Long-Lived Plasma Cells
Typically, after vaccination or infection, the immune system develops long-lived plasma cells that are responsible for producing antibodies against the invading pathogen over extended periods, thereby providing long-term immunity. These plasma cells reside in the bone marrow, providing the body with a memory of past infections and vaccinations, allowing for a swift response upon re-exposure to the pathogen. Dr. McMillan explained the importance of long-lived plasma cells: “When your immune system is faced with a virus or bacteria, it wants to remember the infection. A cohort of plasma cells are sent to the bone marrow, where they’re kept safe in case it has to face this infection again.”
Comparing mRNA Vaccines to Traditional Vaccines
Researchers compared the immune responses to mRNA COVID-19 vaccines with those elicited by traditional vaccines for influenza and tetanus. They found that while vaccines for influenza and tetanus effectively generated long-lived plasma cells in the bone marrow, the mRNA COVID-19 vaccines did not. Specifically, serum IgG levels for SARS-CoV-2 decreased significantly within three to six months post-vaccination and were not associated with the presence of long-term plasma cells.
This discovery may explain why individuals require multiple booster doses of the mRNA COVID-19 vaccine to maintain immunity. The absence of durable plasma cells suggests that the immune system is not retaining a long-term memory of the spike protein antigen introduced by the vaccine.
The Toxin Hypothesis
One hypothesis proposed to explain this phenomenon is that the immune system may be treating the spike protein as a toxin rather than a typical antigen. In immunology, certain toxins, such as endotoxins from gram-negative bacteria like E. coli, elicit a strong immediate immune response. However, these responses do not establish long-term immunity. The body reacts intensely to neutralize the toxin but avoids creating a lasting memory to prevent potential autoimmune reactions or chronic inflammation.
Endotoxins can trigger severe immune reactions leading to conditions like sepsis. The immune system’s strategy is to address the immediate threat without retaining a memory that could cause harm if overactivated in the future. Similarly, if the spike protein is perceived as a toxin, the immune system might be deliberately avoiding the creation of long-lived plasma cells to prevent adverse effects.
Rethinking Vaccination Strategies
This insight raises important questions about the current vaccination strategies against COVID-19. If the immune system inherently avoids establishing long-term memory against the spike protein, relying solely on mRNA vaccines that introduce this protein might not achieve the desired herd immunity. Continuous booster shots may not effectively change this outcome, as the underlying immune response strategy remains the same. Dr. McMillan echoed these concerns, “If the immune system is not trying to remember it, why are we trying to push it?” he asked. “This requires going back to basics and trying to figure out what we’re doing here.”
The implications of this research are significant. It suggests a need to reassess the approach to COVID-19 vaccination, potentially considering alternative vaccine platforms or strategies that could induce a more durable immune response. Traditional vaccines, which use attenuated or inactivated viruses presenting multiple antigens, might offer a solution by engaging the immune system differently.
Moreover, this finding emphasizes the importance of understanding the immune system’s nuanced responses to different types of antigens. It highlights that not all immune responses lead to long-term immunity and that the nature of the antigen plays a critical role in determining the outcome.
The medical community may need to explore whether modifications to the vaccine design could encourage the establishment of long-lived plasma cells. Research into combining mRNA technology with other vaccine platforms or adjuvants that promote durable immunity might be necessary.
In conclusion, the study sheds light on a potential reason for the waning immunity observed with mRNA COVID-19 vaccines. It underscores the complexity of the immune system and the challenges in developing vaccines that not only protect in the short term, but also confer lasting immunity. Ongoing research and open scientific dialogue will be essential in addressing these challenges and improving vaccination strategies to combat COVID-19 effectively.
0 Comments